US 9,764,007 B2Granted

Class of therapeutic protein based molecules

AssigneeAnsun Biopharma, Inc.

InventorsFang Fang, Michael P. Malakhov

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

Claims16

Dependent claims

A method for preparing a pharmaceutical composition, comprising

(a) providing a fusion protein comprising at least one catalytic domain of a sialidase and an anchoring domain, wherein the catalytic domain comprises:
(i) the sequence of amino acids extending from amino acid 274 to amino acid 681 of SEQ ID NO:12, inclusive and lacks the sequence that consists of the sequence extending from amino acid 1 to amino acid 273 and from amino acid 682 to amino acid 901 of SEQ ID NO:12;
(ii) the sequence of amino acids extending from amino acid 290 to amino acid 666 of SEQ ID NO:12, inclusive and lacks the sequence that consists of the sequence extending from amino acid 1 to amino acid 289 and from amino acid 667 to amino acid 901 of SEQ ID NO:12;
or
(iii) the sequence of amino acids extending from amino acid 290 to amino acid 681 of SEQ ID NO:12, inclusive and lacks the sequence that consists of the sequence extending from amino acid 1 to amino acid 289 and from amino acid 682 to amino acid 901 of SEQ ID NO:12;
and
the anchoring domain comprises (SEQ ID NO:7);
and
(b) combining the fusion protein with a pharmaceutically acceptable carrier or diluent thereby creating a pharmaceutical composition.

6 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/954,467Filed 30 Nov 2015 · continuation
Priority: 13 Apr 2004
Published: US 2016/0184407 A130 Jun 2016
Granted: 19 Sep 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification31 codes

A61K 38/47
Hydrolases: acting on glycosyl compounds , e.g. cellulases, lactases
A61K 48/0008
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…
A61P 31/16
For RNA viruses: for influenza or rhinoviruses
C07K 14/47
From vertebrates: from mammals

Family

Application60/561,749Us provisional application · filed 13 Apr 2004
Application60/580,084Us provisional application · filed 16 Jun 2004
Application10/939,262Parent of this continuation · filed 10 Sep 2004
Application12/861,392Parent of this continuation · filed 23 Aug 2010
US 7,807,174 B2Parent of this continuation · filed 5 Oct 2010
Application13/970,229Parent of this continuation · filed 19 Aug 2013
US 8,512,710 B2Parent of this continuation · filed 20 Aug 2013
Application14/274,912Parent of this continuation · filed 12 May 2014
US 8,722,869 B2Parent of this continuation · filed 13 May 2014
US 2016/0184407 A1Pre-grant publication · published 30 Jun 2016
US 9,212,353 B2Parent of this continuation
US 2005/0112751 A1Published application
US 2011/0182875 A1Published application
US 2013/0337540 A1Published application
US 2014/0328820 A1Published application
US 9,764,007 B2This patent

From the US filing history. Foreign family members aren’t listed.